French Drugmaker Gets Warning Letter for Testing Deficiencies, Process Validation Issues

Drug Industry Daily
The FDA hit Biologique Recherche with a warning letter after observing multiple violations at its Paris facility, noting inadequate testing methods, quality control concerns and a lack of validation for manufacturing processes, among other issues.

To View This Article:


Subscribe To Drug Industry Daily